0.8601
Precedente Chiudi:
$1.00
Aprire:
$1.03
Volume 24 ore:
431.57K
Relative Volume:
2.52
Capitalizzazione di mercato:
$11.00M
Reddito:
-
Utile/perdita netta:
$-15.91M
Rapporto P/E:
-0.5952
EPS:
-1.445
Flusso di cassa netto:
$-15.07M
1 W Prestazione:
-29.50%
1M Prestazione:
-55.44%
6M Prestazione:
-46.91%
1 anno Prestazione:
-78.60%
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
LTRN
Lantern Pharma Inc
|
0.8601 | 15.60M | 0 | -15.91M | -15.07M | -1.445 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Lantern Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering - The Globe and Mail
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - biospace.com
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com South Africa
Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw - TradingView
Form 424B5 Lantern Pharma Inc For: 30 September - Investing.com India
Lantern Pharma Inc. (LTRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering - biospace.com
Lantern Pharma raises $4M in registered direct offering - Investing.com
Lantern Pharma announces up to $8M registered direct offering - TradingView
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com Nigeria
Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform - TradingView
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic DevelopmentSlideshow (NASDAQ:LTRN) 2026-09-24 - Seeking Alpha
Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent - The Globe and Mail
LTRN: Open Medicine AI expands its platform, targeting new diseases and broader adoption in drug development - TradingView
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - BioSpace
Lantern Pharma Showcases Open-Medicine AI Growth Strategy - TipRanks
Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com Nigeria
Lantern Pharma to present Open-Medicine AI roadmap, demo, commercial model in live webinar - TradingView
Lantern Pharma receives patent allowance for LP-284 cancer drug By Investing.com - Investing.com South Africa
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas - biospace.com
Lantern Pharma (LTRN) Secures Patent Allowance for Blood Cancer Treatment, Faces Valuation Challenges - GuruFocus
Lantern Pharma secures USPTO notice of allowance for LP-284 patent - TipRanks
Lantern Pharma receives patent allowance for LP-284 cancer drug - Investing.com
Lantern Pharma to host webinar on Open-Medicine AI - TipRanks
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune
Lantern Pharma Inc (NASDAQ: LTRN) Share Price, LTRN Stock News, LTRN Share Price & Updates - kalkine.ca
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript - Benzinga
Lantern Pharma to Present Open-Medicine AI, a Multi-Agentic Platform for End-to-End Therapeutic Development, Business Model, Roadmap, and Value Proposition on September 23 - marketscreener.com
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap - Barchart.com
Lantern Pharma (LTRN) to Host Webinar Highlighting AI-Driven The - GuruFocus
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 - Yahoo Finance
Lantern Pharma Share PriceLTRN, RNS News, Articles, Quotes, & Charts (NASDAQ:LTRN) - Proactive financial news
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - guardonline.com
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Lantern Pharma Earnings Call: AI Spinout, Trial Momentum - TipRanks
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):